



**Osteoporosis Drug Development
Moving Forward
Public Workshop
November 4, 2015**



Discussion Panel Members and Speakers

Robert Adler, MD

Chief, Endocrinology and Metabolism
McGuire Veterans Affairs Medical Center
Richmond, Virginia

Kumpal Madrasi, PhD

ORISE fellow, Office of Pharmacology
Office of Translational Science
CDER, FDA

Shashi Amur, PhD

Scientific Lead, Biomarker Qualification
Office of Translational Science
CDER, FDA

Michael McClung, MD

Director, Oregon Osteoporosis Center
Portland, Oregon

Douglas Bauer, MD

Professor, General Internal Medicine
University of California San Francisco
School of Medicine
San Francisco, California

Joan McGowan, PhD

Director, Division of Musculoskeletal Disease
National Institute of Arthritis, Musculoskeletal
and Skin Disease
National Institutes of Health
Bethesda, Maryland

Samantha Bell

Regulatory Project Manager, Division of
Bone, Reproductive and Urologic Products
CDER, FDA

Bruce Mitlak, MD

Distinguished Fellow
Eli Lilly and Company
Indianapolis, Indiana

Dennis Black, PhD

Professor, Epidemiology and Biostatistics
University of California San Francisco
School of Medicine
San Francisco, California

Thomas Permutt, PhD

Director, Division of Biostatistics II
Office of Translational Science
CDER, FDA

Henry Bone, MD

Internist, Michigan Bone and Mineral Clinic
Detroit, Michigan

Harold Rosen, MD

Assistant Professor of Medicine
Beth Israel Deaconess, Harvard Medical
School
Boston, Massachusetts

Discussion Panel Members and Speakers

Lorraine Fitzpatrick, MD

Chief Medical Officer
Radius Health, Inc.
Waltham, Massachusetts

Arthur Santora, MD, PhD

Scientific Associate Vice President
Clinical Research, Diabetes & Endocrinology
Merck Research Laboratories
Rahway, New Jersey

Jeffry Florian, Ph.D.

Pharmacometrics Team Leader
Office of Clinical Pharmacology
Office of Translational Science
CDER, FDA

Stephan Schmidt, PhD

Assistant Professor, Pharmaceutics
University of Florida College of Pharmacy
Gainesville, Florida

Robert Gagel, MD

Professor, Division of Internal Medicine
University of Texas MD Anderson Cancer
Center
Houston, Texas

Deborah Sellmeyer, MD

Associate Professor of Medicine
Johns Hopkins Bayview Medical Center
Baltimore, Maryland

Andreas Grauer, MD

Executive Medical Director, Global
Development Leader
Amgen

Elizabeth Shane, MD

Professor of Medicine
Columbia University College of Physicians
and Surgeons
New York, New York

Hylton Joffe, MD, MMSc

Director, Division of Bone, Reproductive and
Urologic Products
CDER, FDA

Mahboob Sobhan, PhD

Team Leader, Division of Biostatistics III
Office of Translational Science
CDER, FDA

Theresa Kehoe, MD

Medical Officer, Team Leader, Division of
Bone, Reproductive and Urologic Products
CDER, FDA

John Stinson, MD

Medical Officer, Division of Bone,
Reproductive and Urologic Products
CDER, FDA

Sundeep Khosla, MD

Professor of Medicine and Physiology
Mayo Clinic College of Medicine
Rochester, Minnesota

Stephen Voss, MD

Medical Officer, Division of Bone,
Reproductive and Urologic Products
CDER, FDA

Discussion Panel Members and Speakers

Myong-Jin Kim, PhD

Pharmacology Team Leader
Division of Clinical Pharmacology III
Office of Translational Science
CDER, FDA

Nelson Watts, MD

Director, Mercy Health Osteoporosis and
Bone Health Services
Cincinnati, Ohio

Benjamin Leder, MD

Associate Professor of Medicine
Massachusetts General Hospital, Harvard
Medical School
Boston, Massachusetts

Thomas Weber, MD

Associate Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Li Li, PhD

Pharmacologist
Division of Clinical Pharmacology III
Office of Translational Science
CDER, FDA

Disclosure Information for Panel Members:

FDA is committed to ensuring transparency, balance, and objectivity at this workshop. Potential conflicts of interest or other financial relationships with the manufacturers of commercial products or products under development for osteoporosis are listed below for each participant.

Panel member	Commercial entity and Relationship number
Robert Adler, MD	Amgen 5; Current Osteoporosis Reports 7; National Bone Health Alliance 6
Shashi Amur, PhD	nothing to disclose
Douglas Bauer, MD	nothing to disclose
Samantha Bell	nothing to disclose
Dennis Black, PhD	Alexion 2; Amgen 5; Lilly 5; Radius Pharma 5
Henry Bone, MD	Amgen 2, 5, 8; Merck 2, 5; Mission 5
Lorraine Fitzpatrick, MD	Radius Health 3
Jeffry Florian, PhD	nothing to disclose
Robert Gagel, MD	Astra Zeneca 2; MD Anderson Cancer Center 3; National Bone Health Alliance 6; National Osteoporosis Foundation 6; Paget Foundation 6
Andreas Grauer, MD	Amgen 3
Hylton Joffe, MD	nothing to disclose
Theresa Kehoe, MD	nothing to disclose
Sundeep Khosla, MD	ActiveLife 9, Bone Therapeutics 9
Myong-Jin Kim, PhD	nothing to disclose
Benjamin Leder, MD	Amgen 2, 5; Lilly 2, 5; Merck 2,5
Li Li, PhD	nothing to disclose
Kumpal Madrasi, PhD	nothing to disclose
Michael McClung, MD	Amgen 5; Lilly 5; Merck 5
Joan McGowan, PhD	nothing to disclose
Bruce Mitlak, MD	Lilly 1, 3

Thomas Permutt, PhD	nothing to disclose
Harold Rosen, MD	nothing to disclose
Arthur Santora, MD, PhD	Merck 1, 3
Stephan Schmidt, PhD	
Deborah Sellmeyer, MD	Amgen 9
Elizabeth Shane, MD	Amgen 2; Lilly 2; Merck 2
Mahboob Sobhan, PhD	nothing to disclose
John Stinson, MD	nothing to disclose
Stephen Voss, MD	nothing to disclose
Nelson Watts, MD	Abbvie 5; Amgen 5,8; Janssen 5; Merck 5; Radius 5; Sanofi 5; Shire 5
Thomas Weber, MD	U.C.B. Biosciences 5
<p>Relationship: 1) Stock options or bond holdings in a for-profit corporation; 2) Research grants; 3) Employment (full or part-time); 4) Ownership or partnership; 5) Consulting fees or other remuneration; 6) Non-remuneration positions of influence (officer, board member, trustee, public spokesperson); 7) Receipt of royalties; 8) Speakers bureau; 9) Other</p>	